A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

This study is specifically designed for adults aged 18 to 75 who have Crohn's disease and have already taken part in one of two previous studies (M14-431 or M14-433) for upadacitinib. To join this current study, you must have shown a positive response to the treatment in those earlier studies. You'll also need to have completed all the procedures and visits required in those original studies, though some allowances were made for endoscopy appointments missed due to the COVID-19 pandemic.

You won't be able to join if your doctor believes, for any reason, that the study isn't suitable for you. This could include if you’ve had a serious allergic reaction to upadacitinib or any of its ingredients before, or if you had a bad side effect in the earlier studies that makes this study unsafe for you. Additionally, if you have an active or long-lasting infection that worries your doctor, or if you were found to have certain types of abnormal cell changes or cancer in your colon during your last endoscopy from the previous studies, you wouldn't be able to participate.

If you join this study, your participation will involve continuing with treatment, either with upadacitinib or a placebo (a dummy pill). You'll have regular hospital visits for check-ups and assessments, which might include blood tests, physical examinations, and possibly endoscopies (a procedure to look inside your gut with a camera). These visits help the study team monitor your health, how the medicine is working, and if you experience any side effects. The study aims to follow participants over a long period to see the lasting effects of the treatment.